当前位置:首页 > 成功案例 > 北京神州细胞生物技术集团股份公司

北京神州细胞生物技术集团股份公司


图片.png

北京神州细胞生物技术集团股份公司是由国际知名的生物药研发和产业化专家、新药创制重大专项总体组专家谢良志博士创办的创新型生物制药研发公司,专注于单克隆抗体、重组蛋白、疫苗等生物药产品的研发和产业化。

公司一直致力于通过生命科学和工程技术创新,建立具有领先技术水平和成本优势的生物药研发和生产技术平台,解决新药研发和生产中的技术断点和瓶颈,为全球患者提供高质量并在经济成本方面可被大众承担的生物药,以提高我国和发展中国家患者对高端生物药的可及性。同时公司致力于通过研发在临床上具有差异化竞争优势的同类最佳(Best-in-Class)或“Me-better”创新生物药产品,以实现我国自主研发和生产的生物药进入欧美发达国家市场、惠及全球患者、树立领先生物制药国际品牌的目标。

公司于2020622日首次公开发行股票并在上海证券交易所科创板挂牌上市。

SinoCellTech. is an innovative biopharmaceutical R&D company founded by Dr. Xie Liangzhi, an internationally renowned expert in biopharmaceutical R&D and industrialization, and an expert in new medicine creation. It focuses on the R&D and industrialization of monoclonal antibodies, recombinant proteins, vaccines and other biopharmaceutical products.

Through the innovation of life science and engineering technology, the company has been committed to establishing a leading technology and cost-advantage platform for the R&D and production of biopharmaceuticals, solving the technical breakpoints and bottlenecks in the R&D and production of new medicine, providing high-quality biopharmaceuticals that can be borne by the public in terms of economic cost for patients all over the world, so as to improve the awareness of patients in China and developing countries of high-level biopharmaceuticals medicine accessibility. At the same time, the company is committed to research and develop the best-in-class or "me better" innovative biopharmaceutical products with differentiated competitive advantages in clinical practice, so as to achieve the goal of China's independent R&D and production of biopharmaceuticals to enter the markets of developed countries in Europe and America, benefit patients all over the world, and establish a leading international brand of biopharmaceuticals

On June 22, 2020, the company made an initial public offering and was listed on the science and Technology Innovation Board of Shanghai Stock Exchange.


http://www.sinocelltech.com/


0.175126s